



Diagnostic Imaging of Cancers: Role of PET/CT

Guest Editor:

Dr. Manuel Röhrich

Clinical Cooperation Unit Nuclear
Medicine, German Cancer
Research Center (DKFZ), D-68120
Heidelberg, Germany

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Dear Colleagues,

Positron emission tomography (PET) is becoming increasingly relevant for the diagnostic imaging of cancers. The value of already clinically available tracers, such as ^{18}F -FDG, ^{18}F -, and ^{68}Ga -PSMA ligands, or ^{68}Ga -DOTATOC/DOTATAE, is increasingly recognized by clinicians, and PET imaging plays an emerging role for the workup of various cancers. On the other hand, new PET tracer molecules, including fibroblast activation protein inhibitors (FAPI tracers), estrogen receptor- or HER2-targeted imaging for breast cancer, or CXCR4-targeted imaging of hematological malignancies, provide new insights into the molecular characteristics of cancers and offer new approaches for staging and therapy response evaluation. Beyond new tracers, new PET scanners with markedly increased fields of views allow fast dynamic and parametric imaging of the whole body and are expected to radically change the clinical setting of oncological PET imaging.

In this Special Issue of *Cancers*, we welcome original scientific contributions that focus on innovative clinical and preclinical approaches for the PET imaging of cancers.

Dr. Manuel Röhrich
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)